Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Emergency Use Power Could Expand Under Bill Moving To House Floor

Executive Summary

FDA could get the power to issue an Emergency Use Authorization before a pandemic or other emergency, according to legislation reauthorizing the Pandemic and All-Hazards Preparedness Act.

You may also be interested in...

Bioterror “Strategic Investor” Initiative Must Be Resolved As House, Senate Pass Dueling Bills

House- and Senate-passed bills reauthorizing the 2006 Pandemic and All-Hazards Preparedness Act are similar in many respects in their efforts to accelerate medical countermeasure development. However, the House bill lacks a Senate provision that would allow HHS to contract with a non-profit entity to invest in companies developing countermeasures.

Biosimilar User Fee Negotiations Under Way; Timetable Compressed

FDA has started biosimilar user fee negotiations with industry, although it does not appear the room is overcrowded with participants.

PDUFA V: Emerging Sponsor Communication Issue Resolved And Expanded

FDA and industry plan to create more staff to help deal with simple and clarifying questions from emerging and experienced sponsors during the application review process as part of PDUFA V.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts